Zara Wasim Haidi
Aim: To validate a protocol for noninvasive fetal sex determinationin maternal plasma and demonstrate its applicability toclinical practice.Method: Peripheral blood from 318 pregnant women was collectedfrom 7 to 12 weeks of gestation. Real-time PCR was performedfor multicopy DYS14 marker sequence located withinthe TSPY gene by the TaqMan probe assay. An exogenousspiked-in amplification/ detection system was also used as apositive control for the extraction process. A diagnostic algorithmwas designed using a combination of these two markers.Fetal gender determined by noninvasive prenatal diagnosis(NIPD) was compared with ultrasound results. The Fisher exacttest (two-sided) was used to determine sensitivity and specificitywith 95% confidence intervals (CIs).Results: A single false-positive result was obtained in all 318pregnancies. The overall sensitivity and specificity were 100%(95% CI 97.7–100%) and 99.3% (95% CI 96.4–99.9%), respectively.Pregnancy outcome was obtained in all cases, including154 male-bearing and 164 female-bearing pregnancies.Conclusions: Primer Design Y-chromosome detection kit forfetal sex determination in plasma of early weeks pregnants ishighly accurate and clinically applicable if robust reporting criteriaare applied.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi